Clinical Genomics Technologies
Sydney
About Clinical Genomics Technologies
Clinical Genomics is a privately held biotechnology company developing innovative products for colorectal cancer diagnosis and monitoring. With a broad intellectual property portfolio including more than 20 issued and pending patents, Clinical Genomics has developed and validated a sensitive and specific blood test for colorectal cancer recurrence monitoring that will be launched in the U.S. in 2016. This 2-gene test, which is based on methylated DNA from two genes, BCAT1 and IKZF1, is currently known by its project name GEMINI.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $19.7M
- Funding stage: Early Stage Venture
- Last round: Series B (Jun 2018)
- Website: clinicalgenomics.com
- Phone: (908)300-8673
Industries & Categories
Biotechnology, Genetics, Health Care, Health Diagnostics, Oncology
Social Profiles
Canonical: https://fsome.com/organization/clinical-genomics-technologies-4202 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.